Deal Spree Continues as Celgene Nabs Juno in $9B Deal Post author:Sam Post published:January 21, 2018 Post category:BioPharma The announcement sent shares of Juno soaring more than 27 percent in pre-market trading to $86.26. Source: BioSpace You Might Also Like FDA Grants Orphan Drug Designation To Prometic's PBI-4050 Drug For The Treatment Of Alstr??m Syndrome March 2, 2017 Genentech Shows Off New Mid-Stage DME Data February 11, 2018 Prometic Snags Rare Pediatric Disease Designation from the FDA for its Inter-Alpha-Inhibitor-Prot… March 4, 2018
FDA Grants Orphan Drug Designation To Prometic's PBI-4050 Drug For The Treatment Of Alstr??m Syndrome March 2, 2017
Prometic Snags Rare Pediatric Disease Designation from the FDA for its Inter-Alpha-Inhibitor-Prot… March 4, 2018